Next Article in Journal
Effectiveness of Self-Help Groups and Psychotherapy: Self-Assessment of Patients With Substance Use Disorders
Previous Article in Journal
Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Comparison of the Effects of Glibenclamide on Metabolic Parameters, GLUT1 Expression, and Liver Injury in Rats With Severe and Mild Streptozotocin-Induced Diabetes Mellitus

1
Department of Medical Biochemistry, Faculty of Medicine, University of Latvia
2
Latvian Institute of Organic Synthesis
3
Department of Pathology, Faculty of Medicine, University of Latvia
4
Group of Genomics and Bioinformatics, Institute of Biology, University of Latvia, Latvia
*
Authors to whom correspondence should be addressed.
Medicina 2012, 48(10), 78; https://doi.org/10.3390/medicina48100078
Received: 23 September 2011 / Accepted: 27 August 2012 / Published: 1 September 2012
Background and Objective. Glucose transport via GLUT1 protein could be one of additional mechanisms of the antidiabetic action of sulfonylureas. Here, the GLUT1 gene and the protein expression was studied in rats in the course of severe and mild streptozotocin-induced diabetes mellitus and under glibenclamide treatment.
Material and Methods.
Severe and mild diabetes mellitus was induced using different streptozotocin doses and standard or high fat chow. Rats were treated with glibenclamide (2 mg/kg daily, per os for 6 weeks). The therapeutic effect of glibenclamide was monitored by measuring several metabolic parameters. The GLUT1 mRNA and the protein expression in the kidneys, heart, and liver was studied by means of real-time R T-PCR and immunohistochemistry.
Results
. The glibenclamide treatment decreased the blood glucose concentration and increased the insulin level in both models of severe and mild diabetes mellitus. Severe diabetes mellitus provoked an increase in both GLUT1 gene and protein expression in the kidneys and the heart, which was nearly normalized by glibenclamide. In the kidneys of mildly diabetic rats, an increase in the GLUT1 gene expression was neither confirmed on the protein level nor influenced by the glibenclamide treatment. In the liver of severely diabetic rats, the heart and the liver of mildly diabetic rats, the GLUT1 gene and the protein expression was changed independently of each other, which might be explained by abortive transcription, and pre- and posttranslational modifications of gene expression.
Conclusions. The GLUT1 expression was found to be affected by the glucose and insulin levels and can be modulated by glibenclamide in severely and mildly diabetic rats. Glibenclamide can prevent the liver damage caused by severe hyperglycemia.
Keywords: glibenclamide; GLUT1; kidney; streptozotocin; expression glibenclamide; GLUT1; kidney; streptozotocin; expression
MDPI and ACS Style

Sokolovska, J.; Isajevs, S.; Sugoka, O.; Sharipova, J.; Paramonova, N.; Isajeva, D.; Rostoka, E.; Sjakste, T.; Kalvinsh, I.; Sjakste, N. Comparison of the Effects of Glibenclamide on Metabolic Parameters, GLUT1 Expression, and Liver Injury in Rats With Severe and Mild Streptozotocin-Induced Diabetes Mellitus. Medicina 2012, 48, 78.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop